SYS6041 (Antibody-Drug Conjugate) obtains clinical trial approval in the U.S.

CAR-T Digest - August 2020

14 Apr 2025: SYS6041 (Antibody-Drug Conjugate) obtains clinical trial approval in the U.S.

CSPC Pharmaceutical Group received FDA approval to begin clinical trials in the U.S. for SYS6041, an antibody-drug conjugate
SYS6041 also received approval from China’s National Medical Products Administration in January 2025 for clinical trials
The drug targets advanced solid tumors by binding to tumor receptors, entering cells, and releasing toxins to kill them
Preclinical studies showed strong anti-tumor activity across various cancer types, suggesting high clinical potential
Multiple patent applications for SYS6041 have been submitted both in China and internationally